Oritavancin(CAS: 171099-57-3)

Oritavancin (CAS: 171099-57-3) is subject to regulatory guidelines under the REACH regulations in the EU. In the USA, it is regulated by the FDA for pharmaceutical use. The compound must comply with GHS (Globally Harmonized System) for classification and labeling. EPA regulations govern its environmental release and disposal.

There are several alternatives to Oritavancin in synthesis, including other beta-lactam antibiotics and non-betalactam agents like linezolid. Common substitutes include cephalosporins, and other glycopeptide antibiotics such as vancomycin. The choice of alternative depends on the specific application and pharmacokinetic properties required.

The market for Oritavancin is growing due to its broad-spectrum activity against Gram-positive bacteria. Research trends focus on its efficacy, safety, and potential for treating acute bacterial skin and skin structure infections. Studies are also investigating its use in combination therapies and long-term safety.

Waste containing Oritavancin (CAS: 171099-57-3) should be collected in a leak-proof container and stored away from flammable materials. Incineration is the preferred method for disposal, following local regulations. Non-incinerable waste should be managed by a professional hazardous waste disposal service to ensure compliance with environmental protection laws.